NEWS Release

Tectin™ Phase II Trial Begins in China

Date: July 28, 2004

Toronto Stock Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that the Tectin™Phase II clinical trial in China has commenced to demonstrate the analgesic efficacy of Tectin™ in patients with chronic cancer pain. This is an efficacy trial in which an initial phase of escalating dose to the effective dose (Part I) is followed by a controlled phase (Part II). The total participants for Part I and Part II are approximately 300 patients, and will involve up to 8 SFDA (State Food and Drug Administration) authorized centers across China .

Part I study protocol has been approved by the local Ethic's Committee. This is an open-label, ascending dose efficacy and safety study of Tectin™ in late-stage cancer patients with severe pain. This entire Phase II study is expected to be completed within one year.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, is a sodium channel blocker and is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products visit us at http://www.wextech.ca or call Don Evans or Gordon Stanley, Corporate Communications at 604-683-8880, or at 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.